Drug Combinations: New Rules, New Opportunities

Date: May 22, 2011
Pages: 48
US$ 895.00
License [?]:
Publisher: FirstWord
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)

Download PDF Leaflet

Drug Combinations: New Rules, New Opportunities
Single symptom. Single illness. Single drug.

For years, drug therapy has been built on that basic equation. Yet as genomic biology sheds light on the astonishing intricacy of disease pathology, it is clear that drugs that combine several compounds must be developed in response.

According to Biovista president Dr Aris Persidis, the possibility of such combination drugs “opens up this wonderful world of re-exploration of shelved, ineffective compounds in the pipelines of pharma companies that can be investigated for additive effects.”

This “wonderful world”, however, has its hurdles. While recent US Food and Drug Administration (FDA) guidance offers much-welcomed room for establishing codevelopment strategies, it also opens the door to wider questions regarding pharmacovigilance requirements, additional trials and more complex risk-benefit calculations. What’s more, the FDA strictly limits the scope—for now—of scenarios for codeveloped drugs, indicating approval will not be easy.

In our latest report, Drug Combinations: New Rules, New Opportunities, FirstWord unravels some of these issues by drawing on the insight of 18 experts working in cutting-edge biological research and regulatory affairs. The tightly-written report outlines the guidance offered by the FDA, and explains how it can be deployed to develop effective new treatments. The report also addresses the remaining barriers to development and provides insight into co-development trials as well as discussing commercial factors such as anti-trust, intellectual property and working across different corporate cultures.


The report includes:
  • A concise overview of where codevelopment currently sits and what lies ahead
  • Insight into the FDA guidance and how it can be applied
Key features:
  • Explanation of the FDA’s regulatory approach
  • Examination of legal challenges presented by working collaboratively across companies
  • Four cases studies of companies actively codeveloping or have the potential to do so
  • Overview of non-regulatory issues, such as antitrust, financials, intellectual property and corporate culture


  Deeper biological understanding
  Second-look opportunities
Barriers to development
  FDA's response
    No binding rules


Criteria for codevelopment
  Serious conditions
  Compelling biological rationale
  Not feasible to develop individual agent
Decision tree
  Early human studies
  Clinical pharmacology studies
  Proof of concept studies
  Confirmatory studies


  Early interaction with FDA
  The type of IND required
  Labeling issues
Uncertainties prevail
  Weighing risks
  Next steps


Case study 1: Basic research
Case study 2: Actively seeking partnerships
Case study 3: Big pharma codevelopment program
Case study 4: An innovative trial


Antitrust issues
Financial issues
Intellectual property issues
Corporate culture issues

Skip to top

Ask Your Question

Drug Combinations: New Rules, New Opportunities
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: